Designation of Anti-H5N1 Equine Immunoglobulin F(AB')2 Fragments (Fabenflu) as an orphan drug - Fab'entech

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was established to regulate therapeutic goods and ensure their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework governing the manufacturing, importation, supply, and advertising of therapeutic goods in Australia. The Act aims to protect public health by providing a mechanism for the evaluation and monitoring of therapeutic goods. The designation of Anti-H5N1 equine immunoglobulin F(ab’)2 fragments (FABENFLU) as an orphan drug under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 highlights the policy objective of encouraging the development of treatments for rare or neglected diseases. This particular designation, effective from 12 February 2014, recognises the need for innovative treatments for H5N1 avian influenza, providing incentives for the development of such therapies.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Commonwealth of Australia's Department of Health and Therapeutic Goods Administration, pertains to the regulation of therapeutic goods within Australia. This Act applies broadly to therapeutic goods, including medicines, medical devices, blood, and tissues, and encompasses a wide range of entities such as manufacturers, importers, and sponsors of these goods. The legislation's jurisdiction spans the entire Commonwealth, ensuring uniform standards and regulations across Australia. It includes provisions for the designation of orphan drugs, which are medications intended for rare medical conditions, thus incentivising research and development for such conditions. In this context, Anti-H5N1 equine immunoglobulin F(ab’)2 fragments (FABENFLU) has been designated as an orphan drug specifically for the treatment of passive immunotherapy in cases of post-exposure or suspected post-exposure to H5N1 avian influenza virus. This designation is made under the authority of the Therapeutic Goods Regulations 1990, which allows for flexibility and updates through subordinate instruments, ensuring the Act remains relevant and effective in addressing emerging health concerns.

Key Provisions

The Therapeutic Goods Act 1989 has been amended to designate Anti-H5N1 equine immunoglobulin F(ab’)2 fragments, marketed as FABENFLU, as an orphan drug for the treatment of passive immunotherapy in cases of post-exposure or suspected post-exposure to H5N1 avian influenza virus. This designation is critical for ensuring that there is adequate research and development for treatments that are often overlooked due to the rarity of the condition they target (s 42AD(1)(a)). The sponsor of this therapeutic good is Fab’entech, which has been identified as the entity responsible for the oversight and management of this drug (s 42AD(1)(b)). Entities governed by this Act, particularly the sponsor Fab’entech, have specific obligations under the legislation. These include ensuring that the therapeutic good complies with all relevant regulations, obtaining necessary approvals for clinical trials, and submitting detailed reports to the Therapeutic Goods Administration (TGA). The sponsor must also ensure that the manufacturing processes and facilities adhere to good manufacturing practices, and that any adverse effects are promptly reported to the TGA (s 42AD(2)(b)). The Act mandates that the sponsor maintains thorough documentation to support the safety and efficacy of the drug, which is crucial for regulatory compliance and ongoing monitoring. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in significant consequences. For instance, if Fab’entech fails to report adverse effects or does not maintain proper documentation, they may face penalties. The maximum penalties for non-compliance can include fines and imprisonment. Specifically, under section 33 of the Act, an individual can be fined up to $222,000 or face imprisonment for up to two years, or both, for supplying non-compliant therapeutic goods. Additionally, corporate entities, such as Fab’entech, can face fines of up to $1,110,000 (s 33). These penalties underscore the seriousness with which the Act treats compliance and the protection of public health.